Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers
Acquisition Expands Merck’s Oncology Portfolio with Novel Oral BET Inhibitor, OTX015 KENILWORTH, N.J., Dec. 18, 2014 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has acquired, through a subsidiary, OncoEthix, a Swiss-based [...]